These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 35451899)

  • 1. Characteristics of patients with autonomic dysfunction in the Transthyretin Amyloidosis Outcomes Survey (THAOS).
    Barroso FA; Coelho T; Dispenzieri A; Conceição I; Waddington-Cruz M; Wixner J; Maurer MS; Rapezzi C; Planté-Bordeneuve V; Kristen AV; González-Duarte A; Chapman D; Stewart M; Amass L;
    Amyloid; 2022 Sep; 29(3):175-183. PubMed ID: 35451899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A natural history analysis of asymptomatic
    Coelho T; Conceição I; Waddington-Cruz M; Keohane D; Sultan MB; Chapman D; Amass L;
    Amyloid; 2022 Dec; 29(4):228-236. PubMed ID: 35730447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phenotypic characteristics of F64L, I68L, I107V, and S77Y ATTRv genotypes from the Transthyretin Amyloidosis Outcomes Survey (THAOS).
    Gentile L; Diemberger I; Plante-Bordeneuve V; Mazzeo A; Dori A; Luigetti M; Di Paolantonio A; Dispenzieri A; Grogan M; Waddington Cruz M; Adams D; Inamo J; Kristen AV; Lino Cirami C; Chapman D; Gupta P; Glass O; Amass L
    PLoS One; 2024; 19(1):e0292435. PubMed ID: 38241252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey.
    Nativi-Nicolau J; Siu A; Dispenzieri A; Maurer MS; Rapezzi C; Kristen AV; Garcia-Pavia P; LoRusso S; Waddington-Cruz M; Lairez O; Witteles R; Chapman D; Amass L; Grogan M;
    JACC CardioOncol; 2021 Oct; 3(4):537-546. PubMed ID: 34729526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 15-year consolidated overview of data in over 6000 patients from the Transthyretin Amyloidosis Outcomes Survey (THAOS).
    Gentile L; Coelho T; Dispenzieri A; Conceição I; Waddington-Cruz M; Kristen A; Wixner J; Diemberger I; Gonzalez-Moreno J; Cariou E; Maurer MS; Planté-Bordeneuve V; Garcia-Pavia P; Tournev I; Gonzalez-Costello J; Duarte AG; Grogan M; Mazzeo A; Chapman D; Gupta P; Glass O; Amass L;
    Orphanet J Rare Dis; 2023 Nov; 18(1):350. PubMed ID: 37946256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update.
    Dispenzieri A; Coelho T; Conceição I; Waddington-Cruz M; Wixner J; Kristen AV; Rapezzi C; Planté-Bordeneuve V; Gonzalez-Moreno J; Maurer MS; Grogan M; Chapman D; Amass L;
    Orphanet J Rare Dis; 2022 Jun; 17(1):236. PubMed ID: 35717381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Descriptive Analysis of ATTR Amyloidosis in Spain from the Transthyretin Amyloidosis Outcomes Survey.
    González-Moreno J; Losada-López I; Cisneros-Barroso E; Garcia-Pavia P; González-Costello J; Muñoz-Beamud F; Campistol JM; Fernandez-Torron R; Chapman D; Amass L
    Neurol Ther; 2021 Dec; 10(2):833-845. PubMed ID: 34331265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of Patients with Late- vs. Early-Onset Val30Met Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey (THAOS).
    Waddington-Cruz M; Wixner J; Amass L; Kiszko J; Chapman D; Ando Y;
    Neurol Ther; 2021 Dec; 10(2):753-766. PubMed ID: 34024024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sex Differences in Wild-Type Transthyretin Amyloidosis: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS).
    Campbell CM; LoRusso S; Dispenzieri A; Kristen AV; Maurer MS; Rapezzi C; Lairez O; Drachman B; Garcia-Pavia P; Grogan M; Chapman D; Amass L;
    Cardiol Ther; 2022 Sep; 11(3):393-405. PubMed ID: 35583798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sex-Related Risk of Cardiac Involvement in Hereditary Transthyretin Amyloidosis: Insights From THAOS.
    Caponetti AG; Rapezzi C; Gagliardi C; Milandri A; Dispenzieri A; Kristen AV; Wixner J; Maurer MS; Garcia-Pavia P; Tournev I; Planté-Bordeneuve V; Chapman D; Amass L;
    JACC Heart Fail; 2021 Oct; 9(10):736-746. PubMed ID: 34391735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Same same, but different? The neurological presentation of wildtype transthyretin (ATTRwt) amyloidosis.
    Kleefeld F; Scherret E; Knebel F; Messroghli D; Heidecker B; Wetz C; Schatka I; Barzen G; Tschöpe C; Amthauer H; Hahn K
    Amyloid; 2022 Jun; 29(2):92-101. PubMed ID: 34994254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and apparative investigation of large and small nerve fiber impairment in mixed cohort of ATTR-amyloidosis: impact on patient management and new insights in wild-type.
    Papagianni A; Ihne S; Zeller D; Morbach C; Üçeyler N; Sommer C
    Amyloid; 2022 Mar; 29(1):14-22. PubMed ID: 34632904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Late-onset hereditary ATTR V30M amyloidosis with polyneuropathy: Characterization of Brazilian subjects from the THAOS registry.
    Pinto MV; Pinto LF; Dias M; Rosa RS; Mundayat R; Pedrosa RC; Waddington-Cruz M
    J Neurol Sci; 2019 Aug; 403():1-6. PubMed ID: 31163298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenotypic Differences of Glu89Gln Genotype in ATTR Amyloidosis From Endemic Loci: Update From THAOS.
    Gentile L; Tournev I; Amass L; Chapman D; Mazzeo A;
    Cardiol Ther; 2021 Dec; 10(2):481-490. PubMed ID: 34148211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. THAOS - The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis.
    Coelho T; Maurer MS; Suhr OB
    Curr Med Res Opin; 2013 Jan; 29(1):63-76. PubMed ID: 23193944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey).
    Maurer MS; Hanna M; Grogan M; Dispenzieri A; Witteles R; Drachman B; Judge DP; Lenihan DJ; Gottlieb SS; Shah SJ; Steidley DE; Ventura H; Murali S; Silver MA; Jacoby D; Fedson S; Hummel SL; Kristen AV; Damy T; Planté-Bordeneuve V; Coelho T; Mundayat R; Suhr OB; Waddington Cruz M; Rapezzi C;
    J Am Coll Cardiol; 2016 Jul; 68(2):161-72. PubMed ID: 27386769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood pressure and orthostatic hypotension as measures of autonomic dysfunction in patients from the transthyretin amyloidosis outcomes survey (THAOS).
    González-Duarte A; Barroso F; Mundayat R; Shapiro B
    Auton Neurosci; 2019 Dec; 222():102590. PubMed ID: 31726319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and Genotype Characteristics and Symptom Migration in Patients With Mixed Phenotype Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey.
    González-Moreno J; Dispenzieri A; Grogan M; Coelho T; Tournev I; Waddington-Cruz M; Wixner J; Diemberger I; Garcia-Pavia P; Chapman D; Gupta P; Glass O; Amass L;
    Cardiol Ther; 2024 Mar; 13(1):117-135. PubMed ID: 38117424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis.
    Aimo A; Rapezzi C; Perfetto F; Cappelli F; Palladini G; Obici L; Merlini G; Di Bella G; Serenelli M; Zampieri M; Milani P; Licordari R; Teresi L; Ribarich N; Castiglione V; Quattrone F; De Rosis S; Vergaro G; Panichella G; Emdin M; Passino C
    Eur J Clin Invest; 2021 Nov; 51(11):e13598. PubMed ID: 33982288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT.
    Rapezzi C; Elliott P; Damy T; Nativi-Nicolau J; Berk JL; Velazquez EJ; Boman K; Gundapaneni B; Patterson TA; Schwartz JH; Sultan MB; Maurer MS
    JACC Heart Fail; 2021 Feb; 9(2):115-123. PubMed ID: 33309574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.